Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

Alamar Biosciences, Inc. California

View original content:https://www.prnewswire.co.uk/news-releases/alamar-biosciences-announces-the-commercial-launch-of-ultra-high-sensitivity-nulisaseq-cns-disease-panel-120-and-nulisaqpcr-ptau-217-assays-302080017.html